In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

US FDA Meeting Requested

 
• By Sushmita Panda
  
Cancer Research
Immutep said it will meet with regulators to discuss next steps after strong OS data for combo therapy in 1L HNSCC. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas